Replies to post #770781 on NorthWest Biotherapeutics Inc (NWBO)

[exwannabe]

I agree that the patent looks like it matches the 2024 mods that were adding extra functionality. But that is not the design they are going forward with because they decided it was too large.

Per the 10K:

During 2024, the Company’s Flaskworks subsidiary and a specialized contractor developed a GMP-compatible prototype of the Flaskworks system for a “closed” manufacturing process for DCVax-L. Another prototype, with smaller dimensions, had been developed in 2023. The Company has determined that the smaller prototype will be preferable, to enable more units to fit in each manufacturing lab. Production of the GMP-grade units will be timed to coincide with the timing for buildout of Grade C labs in the Sawston facility. When the GMP-grade units are delivered, Advent BioServices will undertake qualification and validation of those units, conduct engineering runs and collect data, and apply to regulators for approval to use the system to produce DCVax-L for patients. As previously reported, the Company views the Flaskworks program and system as a centerpiece of efforts toward scale-up for potential commercial operations.

BTW, I take the NWBO explanation in the 10K with a grain of salt.

[StockFollower]

Hyperopia - thanks for the correction. I will leave technology issues to experts like you in the future. I appreciate your contributions and insights!

In the future I will stick to what I am capable of doing, which is clicking "like" on posts that I find informative.

Thank you,

SF

[Doc logic]

hyperopia,

Hoping you can save me some time digging. At one time I read that Eden might also be capable of T-cell culture and amplification. I have not looked closely lately at the distinction between the latest models and whether or not this still a capability in one of the more developed systems. Wondering if you know offhand. Best wishes.

[beartrap12]

hyperopia, thanks for jumping in here and explaining the new and improved Flaskworks product. It sounds like we should expect even more efficacy and quality control once this new Flaskworks unit is put to work.

[ATLnsider]

Thanks for posting this hyperopia.

You are correct that this new improved version of Flaskworks Eden system is not about manufacturing CAR-T cells. It is completely about manufacturing adherent dendritic cell therapies, like DCVax-L and DCVax Direct.

This new improved system will produce a greater yield of dendritic cells, and the dendritic cells will be more potent, have increased purity, and less impurities.

This new device can be configured with multiple bioreactors, and will allow for significantly greater global manufacturing scale capacity. This will truly allow the DCVax dendritic cell vaccine platform to scale to treat all or most solid tumor cancers in the future.